Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

Cerevel Therapeutics is expecting to presented data from studying Tavapadon in patients with early-stage Parkinson’s Disease, at the 2019 International Congress of Parkinson’s Disease and Movement Disorders.

BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease at the 2019 International Congress of Parkinson’s Disease and Movement Disorders^®, taking place from September 22-26 in Nice, France. Tavapadon is a novel, investigational, orally-administered, selective partial agonist of the dopamine D1 and D5 receptors.

Details of the poster presentation are as follows:

Title: Efficacy, Safety and Tolerability of Tavapadon in Subjects with Early Stage Parkinson’s Disease

Abstract Number: 98

Authors: David L. Gray, Robert Riesenberg, John Werth, Yao Zhang, Mark Versavel, Sridhar Duvvuri

Session Title: Clinical Trials, Pharmacology and Treatment

Date/Time: Monday, September 23, 2019 from 1:45 to 3:15 p.m. CEST (7:45 to 9:15 a.m. EDT)

Location: Nice Acropolis Convention Centre, 1 Esplanade Kennedy 06364, Nice Cedex 4, France